CONGRESS COVERAGE: EHA 2020 – FOCUS ON LEUKEMIA AND MDS
Clinical trials updates, emerging therapies, and future directions in acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML)
FACULTY CO-CHAIR
Dieter Hoelzer, MD, PhD
University of Frankfurt, Frankfurt, Germany
FACULTY CO-CHAIR
Elias Jabbour, MD
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Faculty Members
Daniel DeAngelo, MD, PhD
Dana-Farber Cancer Institute, Boston, MA, US
Naval Daver, MD
University of Texas MD Anderson Cancer Center, Houston, TX, US
Gert Ossenkoppele, MD, PhD
VU Medical Center, Amsterdam, The Netherlands
Josep-Maria Ribera, MD, PhD
Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
Valeria Santini, MD
University of Florence, Florence, Italy
Jorge Sierra, MD, PhD
Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
REPORT TOPICS INCLUDE
- MDS
- Elderly/Unfit AML Patients
- IDH– and FLT3-Mutant AML Patients
- Emerging Immune Therapies in AML
- Updates in ALL
- Strategic Insights and Key Takeaways
